Ocumension Therapeutics
5DG
Company Profile
Business description
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
Contact
No. 1858 Yinzhongnan Road
Guoxiang Subdistrict
Wuzhong District
SuzhouJiangsu
CHNT: +86 2161493800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
489
Stocks News & Analysis
stocks
James Hardie transfers of share listing to New York Stock Exchange
The change is a result of the controversial Azek acquisition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,926.20 | 80.60 | -0.89% |
CAC 40 | 7,798.22 | 24.45 | -0.31% |
DAX 40 | 24,307.80 | 18.29 | 0.08% |
Dow JONES (US) | 44,484.13 | 141.94 | 0.32% |
FTSE 100 | 9,012.99 | 20.87 | 0.23% |
HKSE | 24,994.14 | 168.48 | 0.68% |
NASDAQ | 21,026.24 | 130.59 | 0.62% |
Nikkei 225 | 39,819.11 | 82.08 | -0.21% |
NZX 50 Index | 12,961.51 | 81.11 | 0.63% |
S&P 500 | 6,325.16 | 28.37 | 0.45% |
S&P/ASX 200 | 8,668.20 | 89.00 | -1.02% |
SSE Composite Index | 3,559.79 | 25.31 | 0.72% |